$INSP
Inspire Medical Systems, Inc. Stock $insp

$insp Overview Financials Valuation SEC Filings Company Website

2021 Q4 Form 10-Q Financial Statement

#000160955021000048 Filed on November 02, 2021

Income Statement

Concept	2021 Q4	2021 Q3	2020 Q3
Revenue	$78.40M	$61.69M	$35.84M
YoY Change	70.4%	72.1%	71.81%
Cost Of Revenue	$11.16M	$8.624M	$5.211M
YoY Change	55.81%	65.5%	50.78%
Gross Profit	$67.24M	$53.06M	$30.63M
YoY Change	73.09%	73.23%	75.98%
Gross Profit Margin	85.77%	86.02%	85.46%
Selling, General & Admin	$58.77M	$53.24M	$33.22M
YoY Change	52.13%	60.27%	48.11%
% of Gross Profit	87.4%	100.34%	108.45%
Research & Development	$10.29M	$9.614M	$7.307M
YoY Change	41.21%	31.57%	101.68%
% of Gross Profit	15.31%	18.12%	23.85%
Depreciation & Amortization	$344.0K	$336.0K	$210.0K
YoY Change	37.6%	60.0%	61.54%
% of Gross Profit	0.51%	0.63%	0.69%
Operating Expenses	$69.06M	$62.86M	$40.52M
YoY Change	50.43%	55.11%	55.52%
Operating Profit	-$1.821M	-$9.796M	-$9.892M
YoY Change	-74.21%	-0.97%	14.35%
Interest Expense	-$523.0K	$537.0K	$533.0K
YoY Change	13.7%	0.75%	0.76%
% of Operating Profit
Other Income/Expense, Net	-$27.00K	-$548.0K	-$406.0K
YoY Change	-145.0%	34.98%	-200.5%
Pretax Income	-$2.371M	-$10.34M	-$10.30M
YoY Change	-68.22%	0.45%	24.87%
Income Tax	$20.00K	$0.00	$100.0K
% Of Pretax Income
Net Earnings	-$2.391M	-$10.35M	-$10.39M
YoY Change	-68.05%	-0.37%	25.92%
Net Earnings / Revenue	-3.05%	-16.77%	-28.97%
Basic Earnings Per Share		-$0.38	-$0.39
Diluted Earnings Per Share	-$87.34K	-$0.38	-$0.39
COMMON SHARES
Basic Shares Outstanding	27.36M shares	27.30M shares	26.84M shares
Diluted Shares Outstanding		27.30M shares	26.84M shares

Balance Sheet

Concept	2021 Q4	2021 Q3	2020 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$214.5M	$210.2M	$234.6M
YoY Change	-8.5%	-10.4%	54.75%
Cash & Equivalents	$214.5M	$210.2M	$178.7M
Short-Term Investments	$0.00	$0.00	$55.90M
Other Short-Term Assets	$2.660M	$3.046M	$2.200M
YoY Change	33.0%	38.45%	-31.25%
Inventory	$17.23M	$15.57M	$8.966M
Prepaid Expenses	$2.660M	$3.046M	$2.219M
Receivables	$34.18M	$26.68M	$21.10M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$268.5M	$255.5M	$266.9M
YoY Change	-0.49%	-4.28%	56.59%
LONG-TERM ASSETS
Property, Plant & Equipment	$8.486M	$7.915M	$4.309M
YoY Change	59.78%	83.69%	56.29%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$9.938M	$9.984M	$0.00
YoY Change			-100.0%
Other Assets	$204.0K	$204.0K	$400.0K
YoY Change	0.0%	-49.0%	0.0%
Total Long-Term Assets	$26.55M	$23.40M	$4.861M
YoY Change	134.51%	381.36%	-61.91%
TOTAL ASSETS
Total Short-Term Assets	$268.5M	$255.5M	$266.9M
Total Long-Term Assets	$26.55M	$23.40M	$4.861M
Total Assets	$295.1M	$278.9M	$271.8M
YoY Change	4.94%	2.62%	48.33%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$11.67M	$9.989M	$6.700M
YoY Change	62.01%	49.09%	39.58%
Accrued Expenses	$20.45M	$17.48M	$11.46M
YoY Change	51.33%	52.57%	45.65%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$9.188M	$6.125M
YoY Change
Total Short-Term Liabilities	$41.31M	$33.59M	$18.20M
YoY Change	99.31%	84.59%	43.26%
LONG-TERM LIABILITIES
Long-Term Debt	$15.80M	$18.80M	$24.70M
YoY Change	-36.04%	-23.89%	0.82%
Other Long-Term Liabilities	$134.0K	$124.0K	$74.00K
YoY Change	57.65%	67.57%
Total Long-Term Liabilities	$134.0K	$124.0K	$74.00K
YoY Change	-99.56%	67.57%	-99.7%
TOTAL LIABILITIES
Total Short-Term Liabilities	$41.31M	$33.59M	$18.20M
Total Long-Term Liabilities	$134.0K	$124.0K	$74.00K
Total Liabilities	$66.04M	$58.59M	$42.96M
YoY Change	28.37%	36.39%	15.58%
SHAREHOLDERS EQUITY
Retained Earnings	-$279.4M	-$277.0M	-$229.9M
YoY Change	17.71%	20.51%	34.36%
Common Stock	$27.00K	$27.00K	$27.00K
YoY Change	0.0%	0.0%	12.5%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$229.0M	$220.3M	$228.8M
YoY Change
Total Liabilities & Shareholders Equity	$295.1M	$278.9M	$271.8M
YoY Change	4.94%	2.62%	48.33%

Cashflow Statement

Concept	2021 Q4	2021 Q3	2020 Q3
OPERATING ACTIVITIES
Net Income	-$2.391M	-$10.35M	-$10.39M
YoY Change	-68.05%	-0.37%	25.92%
Depreciation, Depletion And Amortization	$344.0K	$336.0K	$210.0K
YoY Change	37.6%	60.0%	61.54%
Cash From Operating Activities	$734.0K	-$338.0K	-$8.910M
YoY Change	-117.86%	-96.21%	203.06%
INVESTING ACTIVITIES
Capital Expenditures	-$533.0K	-$1.151M	-$1.210M
YoY Change	-12.62%	-4.88%	13.08%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$31.30M	-$24.72M
YoY Change	-100.0%	-226.62%	-4514.29%
Cash From Investing Activities	-$533.0K	$30.15M	-$25.93M
YoY Change	-104.68%	-216.27%	5086.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	4.076M	3.843M	2.310M
YoY Change	-10.02%	66.36%	1115.79%
NET CHANGE
Cash From Operating Activities	734.0K	-338.0K	-8.910M
Cash From Investing Activities	-533.0K	30.15M	-25.93M
Cash From Financing Activities	4.076M	3.843M	2.310M
Net Change In Cash	4.277M	33.65M	-32.53M
YoY Change	-63.82%	-203.46%	900.92%
FREE CASH FLOW
Cash From Operating Activities	$734.0K	-$338.0K	-$8.910M
Capital Expenditures	-$533.0K	-$1.151M	-$1.210M
Free Cash Flow	$1.267M	$813.0K	-$7.700M
YoY Change	-136.2%	-110.56%	311.76%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Entity Central Index Key EntityCentralIndexKey	0001609550
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2020Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.39
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2021
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
CY2020Q1	us-gaap	Accounting Standards Update Extensible List AccountingStandardsUpdateExtensibleList	http://fasb.org/us-gaap/2021-01-31#AccountingStandardsUpdate201613Member
CY2021Q3	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2021-01-31#AccruedLiabilitiesCurrent
CY2020Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2021-01-31#AccruedLiabilitiesCurrent
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2021-09-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-38468
	dei	Entity Registrant Name EntityRegistrantName	Inspire Medical Systems, Inc.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	26-1377674
	dei	Entity Address Address Line1 EntityAddressAddressLine1	5500 Wayzata Blvd.
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 1600
	dei	Entity Address City Or Town EntityAddressCityOrTown	Golden Valley
	dei	Entity Address State Or Province EntityAddressStateOrProvince	MN
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	55416
	dei	City Area Code CityAreaCode	844
	dei	Local Phone Number LocalPhoneNumber	672-4357
	dei	Security12b Title Security12bTitle	Common Stock, $0.001 par value per share
	dei	Trading Symbol TradingSymbol	INSP
	dei	Security Exchange Name SecurityExchangeName	NYSE
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	false
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2021Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	27358099	shares
CY2021Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	210200000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	190518000	USD
CY2021Q3	us-gaap	Short Term Investments ShortTermInvestments	0	USD
CY2020Q4	us-gaap	Short Term Investments ShortTermInvestments	43844000	USD
CY2021Q3	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	95000	USD
CY2020Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	42000	USD
CY2021Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	26675000	USD
CY2020Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	25063000	USD
CY2021Q3	us-gaap	Inventory Net InventoryNet	15574000	USD
CY2020Q4	us-gaap	Inventory Net InventoryNet	8479000	USD
CY2021Q3	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	3046000	USD
CY2020Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	1965000	USD
CY2021Q3	us-gaap	Assets Current AssetsCurrent	255495000	USD
CY2020Q4	us-gaap	Assets Current AssetsCurrent	269869000	USD
CY2021Q3	us-gaap	Long Term Investments LongTermInvestments	9984000	USD
CY2020Q4	us-gaap	Long Term Investments LongTermInvestments	0	USD
CY2021Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	7915000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5311000	USD
CY2021Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	5296000	USD
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	5805000	USD
CY2021Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	204000	USD
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	204000	USD
CY2021Q3	us-gaap	Assets Assets	278894000	USD
CY2020Q4	us-gaap	Assets Assets	281189000	USD
CY2021Q3	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	9989000	USD
CY2020Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	7209000	USD
CY2021Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	17477000	USD
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	13516000	USD
CY2021Q3	us-gaap	Notes Payable Current NotesPayableCurrent	6125000	USD
CY2020Q4	us-gaap	Notes Payable Current NotesPayableCurrent	0	USD
CY2021Q3	us-gaap	Liabilities Current LiabilitiesCurrent	33591000	USD
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	20725000	USD
CY2021Q3	us-gaap	Long Term Notes Payable LongTermNotesPayable	18799000	USD
CY2020Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	24746000	USD
CY2021Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	6080000	USD
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	5886000	USD
CY2021Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	124000	USD
CY2020Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	85000	USD
CY2021Q3	us-gaap	Liabilities Liabilities	58594000	USD
CY2020Q4	us-gaap	Liabilities Liabilities	51442000	USD
CY2021Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2020Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2021Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2020Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2020Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2020Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q3	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2020Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	220300000	USD
CY2021Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2021Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	27350959	shares
CY2021Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	27350959	shares
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	27069276	shares
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	27069276	shares
CY2021Q3	us-gaap	Common Stock Value CommonStockValue	27000	USD
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	27000	USD
CY2021Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	497280000	USD
CY2020Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	467038000	USD
CY2021Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-9000	USD
CY2020Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	29000	USD
CY2021Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-276998000	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-237347000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	229747000	USD
CY2021Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	278894000	USD
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	281189000	USD
CY2021Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	61685000	USD
CY2020Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	35842000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	154996000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	69372000	USD
CY2021Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	8624000	USD
CY2020Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	5211000	USD
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	22123000	USD
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	10462000	USD
CY2021Q3	us-gaap	Gross Profit GrossProfit	53061000	USD
CY2020Q3	us-gaap	Gross Profit GrossProfit	30631000	USD
	us-gaap	Gross Profit GrossProfit	132873000	USD
	us-gaap	Gross Profit GrossProfit	58910000	USD
CY2021Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	9614000	USD
CY2020Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	7307000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	27056000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	18807000	USD
CY2021Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	53243000	USD
CY2020Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	33216000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	143846000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	89249000	USD
CY2021Q3	us-gaap	Operating Expenses OperatingExpenses	62857000	USD
CY2020Q3	us-gaap	Operating Expenses OperatingExpenses	40523000	USD
	us-gaap	Operating Expenses OperatingExpenses	170902000	USD
	us-gaap	Operating Expenses OperatingExpenses	108056000	USD
CY2021Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-9796000	USD
CY2020Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-9892000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-38029000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-49146000	USD
CY2021Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	22000	USD
CY2020Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	125000	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	110000	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	1015000	USD
CY2021Q3	us-gaap	Interest Expense InterestExpense	537000	USD
CY2020Q3	us-gaap	Interest Expense InterestExpense	533000	USD
	us-gaap	Interest Expense InterestExpense	1590000	USD
	us-gaap	Interest Expense InterestExpense	1584000	USD
CY2021Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-33000	USD
CY2020Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	2000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-90000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	83000	USD
CY2021Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-548000	USD
CY2020Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-406000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1570000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-486000	USD
CY2021Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-10344000	USD
CY2020Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-10298000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-39599000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-49632000	USD
CY2021Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	3000	USD
CY2020Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	87000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	52000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	87000	USD
CY2021Q3	us-gaap	Profit Loss ProfitLoss	-10347000	USD
CY2020Q3	us-gaap	Profit Loss ProfitLoss	-10385000	USD
	us-gaap	Profit Loss ProfitLoss	-39651000	USD
	us-gaap	Profit Loss ProfitLoss	-49719000	USD
CY2021Q3	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	3000	USD
CY2020Q3	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	-81000	USD
	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	-38000	USD
	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	-29000	USD
CY2021Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-10344000	USD
CY2020Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-10466000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-39689000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-49748000	USD
CY2021Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.38
CY2021Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.38
CY2021Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	27300377	shares
CY2020Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	26835603	shares
CY2020Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	26835603	shares
CY2020Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.39
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.46
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.46
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.93
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.93
CY2021Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	27300377	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	27225499	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	27225499	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	25767497	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	25767497	shares
CY2020Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	229747000	USD
CY2021Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	3550000	USD
CY2021Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	73000	USD
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	5997000	USD
CY2021Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-20000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-16216000	USD
CY2021Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	223131000	USD
CY2021Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1719000	USD
CY2021Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	72000	USD
CY2021Q2	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	1760000	USD
CY2021Q2	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	6341000	USD
CY2021Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-21000	USD
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-13088000	USD
CY2021Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	219914000	USD
CY2021Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	3843000	USD
CY2021Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	77000	USD
CY2021Q3	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	6810000	USD
CY2021Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	3000	USD
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-10347000	USD
CY2021Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	220300000	USD
CY2019Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	139835000	USD
CY2020Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	787000	USD
CY2020Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	72000	USD
CY2020Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	2749000	USD
CY2020Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	193000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-16245000	USD
CY2020Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	127403000	USD
CY2020Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	732000	USD
CY2020Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	73000	USD
CY2020Q2	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	1059000	USD
CY2020Q2	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	2903000	USD
CY2020Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-141000	USD
CY2020Q2	us-gaap	Net Income Loss NetIncomeLoss	-23089000	USD
CY2020Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	233594000	USD
CY2020Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	2312000	USD
CY2020Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	72000	USD
CY2020Q3	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	3311000	USD
CY2020Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-81000	USD
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	-10385000	USD
CY2020Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	228823000	USD
	us-gaap	Profit Loss ProfitLoss	-39651000	USD
	us-gaap	Profit Loss ProfitLoss	-49719000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	874000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	587000	USD
	us-gaap	Investment Income Amortization Of Premium InvestmentIncomeAmortizationOfPremium	15000	USD
	us-gaap	Investment Income Amortization Of Discount InvestmentIncomeAmortizationOfDiscount	66000	USD
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	178000	USD
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	166000	USD
	us-gaap	Operating Lease Expense OperatingLeaseExpense	509000	USD
	us-gaap	Operating Lease Expense OperatingLeaseExpense	743000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	19148000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	8963000	USD
	insp	Sharebased Compensation Noncash Services SharebasedCompensationNoncashServices	222000	USD
	insp	Sharebased Compensation Noncash Services SharebasedCompensationNoncashServices	217000	USD
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-53000	USD
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	89000	USD
	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	1743000	USD
	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	7921000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	7095000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	3132000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1081000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	15000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	3490000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	2262000	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	4228000	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-931000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-20853000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-48935000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	4135000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1851000	USD
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	9993000	USD
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	52721000	USD
	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	43800000	USD
	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	129803000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	29672000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	75231000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	9112000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	3831000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	124654000	USD
	insp	Proceeds From Issuance Of Common Stock From Employee Stock Purchase Plan ProceedsFromIssuanceOfCommonStockFromEmployeeStockPurchasePlan	1760000	USD
	insp	Proceeds From Issuance Of Common Stock From Employee Stock Purchase Plan ProceedsFromIssuanceOfCommonStockFromEmployeeStockPurchasePlan	1059000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	10872000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	129544000	USD
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-9000	USD
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	5000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	19682000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	155845000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	190518000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	22860000	USD
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	210200000	USD
CY2020Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	178705000	USD
	us-gaap	Interest Paid Net InterestPaidNet	1417000	USD
	us-gaap	Interest Paid Net InterestPaidNet	1422000	USD
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	657000	USD
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	0	USD
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	100000	USD
CY2020	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	100000	USD
CY2021Q3	us-gaap	Debt Securities Available For Sale Realized Gain DebtSecuritiesAvailableForSaleRealizedGain	0	USD
CY2021Q3	us-gaap	Debt Securities Available For Sale Realized Gain DebtSecuritiesAvailableForSaleRealizedGain	0	USD
	us-gaap	Debt Securities Available For Sale Realized Gain DebtSecuritiesAvailableForSaleRealizedGain	100000	USD
	us-gaap	Debt Securities Available For Sale Realized Gain DebtSecuritiesAvailableForSaleRealizedGain	100000	USD
CY2020Q4	insp	Investments Allowance For Credit Loss InvestmentsAllowanceForCreditLoss	0	USD
CY2021Q3	insp	Investments Allowance For Credit Loss InvestmentsAllowanceForCreditLoss	0	USD
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Concentration of Credit Risk</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments, which potentially subject us to concentrations of credit risk, consist principally of cash equivalents, investments, and accounts receivable. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our investment policy limits investments to certain types of debt securities issued by the U.S. government and its agencies, corporations with investment-grade credit ratings, or commercial paper and money market funds issued by the highest quality financial and non-financial companies. We place restrictions on maturities and concentration </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">by type and issuer. We are exposed to credit risk in the event of a default by the issuers of these securities to the extent recorded on the balance sheets. However, as of September 30, 2021 and December 31, 2020, we limited our credit risk associated with cash equivalents by placing investments with banks we believe are highly creditworthy.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that the credit risk in our accounts receivable is mitigated by our credit evaluation process, relatively short collection terms, and dispersion of our customer base. We generally do not require collateral, and losses on accounts receivable have historically been within management's expectations.</span></div>
CY2021Q3	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	1865000	USD
CY2020Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	892000	USD
CY2021Q3	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	13709000	USD
CY2020Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	7587000	USD
CY2021Q3	us-gaap	Inventory Net InventoryNet	15574000	USD
CY2020Q4	us-gaap	Inventory Net InventoryNet	8479000	USD
CY2021Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2708000	USD
CY2021Q3	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	300000	USD
CY2020Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	100000	USD
CY2021Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	10623000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	7156000	USD
CY2020Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1845000	USD
CY2021Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	7915000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5311000	USD
CY2021Q3	us-gaap	Depreciation And Amortization DepreciationAndAmortization	300000	USD
CY2020Q3	us-gaap	Depreciation And Amortization DepreciationAndAmortization	200000	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	900000	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	600000	USD
CY2021Q3	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	14876000	USD
CY2020Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	11965000	USD
CY2020Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1391000	USD
CY2021Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	17477000	USD
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	13516000	USD
CY2021Q3	us-gaap	Interest Payable Current InterestPayableCurrent	155000	USD
CY2020Q4	us-gaap	Interest Payable Current InterestPayableCurrent	160000	USD
CY2021Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	27000	USD
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	0	USD
CY2021Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	2419000	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2021Q3	us-gaap	Advertising Expense AdvertisingExpense	13400000	USD
CY2020Q3	us-gaap	Advertising Expense AdvertisingExpense	6800000	USD
	us-gaap	Advertising Expense AdvertisingExpense	34000000	USD
	us-gaap	Advertising Expense AdvertisingExpense	18200000	USD
CY2021Q3	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	0	USD
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	0	USD
CY2021Q3	us-gaap	Area Of Real Estate Property AreaOfRealEstateProperty	25000	sqft
CY2021Q3	insp	Lessee Operating Lease Number Of Renewal Options LesseeOperatingLeaseNumberOfRenewalOptions	1	renewal_option
CY2021Q3	us-gaap	Lessee Operating Lease Renewal Term LesseeOperatingLeaseRenewalTerm	P5Y
CY2021Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	3600000	USD
CY2021Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	5296000	USD
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	5805000	USD
CY2021Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	27000	USD
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	0	USD
CY2021Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	6080000	USD
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	5886000	USD
CY2021Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	6107000	USD
CY2020Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	5886000	USD
CY2021Q3	us-gaap	Lessee Operating Lease Remaining Lease Term LesseeOperatingLeaseRemainingLeaseTerm	P6Y8M12D
CY2021Q3	us-gaap	Lessee Operating Lease Discount Rate LesseeOperatingLeaseDiscountRate	0.052
CY2021Q3	us-gaap	Operating Lease Payments OperatingLeasePayments	100000	USD
CY2020Q3	us-gaap	Operating Lease Payments OperatingLeasePayments	300000	USD
	us-gaap	Operating Lease Payments OperatingLeasePayments	100000	USD
	us-gaap	Operating Lease Payments OperatingLeasePayments	800000	USD
CY2021Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear	0	USD
CY2021Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	9188000	USD
CY2021Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	12250000	USD
CY2021Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	3062000	USD
CY2021Q3	us-gaap	Long Term Debt LongTermDebt	24500000	USD
CY2021Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	6810000	USD
CY2020Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3311000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	19148000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	8963000	USD
CY2021Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	6810000	USD
CY2020Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3311000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	19148000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	8963000	USD
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2857564	shares
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	66.09
CY2021Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y10M24D
CY2020Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Outstanding SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding	351626000	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	184845	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	208.12
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	269212	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	33.92
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Vested SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested	47176000	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	93790	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	113.37
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2679407	shares
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	77.47
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y3M18D
CY2021Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Outstanding SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding	416515000	USD
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	1355413	shares
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	28.54
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P6Y1M6D
	insp	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Exercisable ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExercisable	276959000	USD
CY2021Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	70000000	USD
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y6M
CY2021Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2020Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	100000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	100000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	100000	USD
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	100000	USD
CY2021Q3	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	100000	USD
CY2021Q3	us-gaap	Significant Change In Unrecognized Tax Benefits Is Reasonably Possible Amount Of Unrecorded Benefit SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit	0	USD
	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	segment
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	154996000	USD
CY2021Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	61685000	USD
CY2020Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	35842000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	69372000	USD
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2687806	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2514801	shares

Files In Submission

Name	View Source	Status
0001609550-21-000048-index-headers.html	Edgar Link	pending
0001609550-21-000048-index.html	Edgar Link	pending
0001609550-21-000048.txt	Edgar Link	pending
0001609550-21-000048-xbrl.zip	Edgar Link	pending
a2021-q3ex31x1.htm	Edgar Link	pending
a2021-q3ex31x2.htm	Edgar Link	pending
a2021-q3ex32x1.htm	Edgar Link	pending
a2021-q3ex32x2.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
insp-20210930.htm	Edgar Link	pending
insp-20210930.xsd	Edgar Link	pending
insp-20210930_cal.xml	Edgar Link	unprocessable
insp-20210930_def.xml	Edgar Link	unprocessable
insp-20210930_g1.jpg	Edgar Link	pending
insp-20210930_htm.xml	Edgar Link	completed
insp-20210930_lab.xml	Edgar Link	unprocessable
insp-20210930_pre.xml	Edgar Link	unprocessable
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$INSP
Inspire Medical Systems, Inc. Stock $insp

2021 Q4 Form 10-Q Financial Statement

#000160955021000048 Filed on November 02, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$INSP Inspire Medical Systems, Inc. Stock $insp

2021 Q4 Form 10-Q Financial Statement

#000160955021000048 Filed on November 02, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$INSP
Inspire Medical Systems, Inc. Stock $insp